Document is current
Any future updates will be listed below
-
Authors
Asciak, Lisa https://orcid.org/0009-0008-8285-198X
Kyeremeh, Justicia
Luo, Xichun
Kazakidi, Asimina https://orcid.org/0000-0001-7124-4123
Connolly, Patricia
Picard, Frederic
O’Neill, Kevin
Tsaftaris, Sotirios A.
Stewart, Grant D.
Shu, Wenmiao https://orcid.org/0000-0002-1220-361X
-
Funding
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/X033686/1, EP/W004860/1, EP/T024844/1, EP/X033686/1)
- License Information
-
More Information
Article History
Received: 12 June 2024
Accepted: 22 December 2024
First Online: 15 January 2025
Competing interests
: G.D.S. has received educational grants from Pfizer, AstraZeneca, and Intuitive. Surgical consultancy fees from Pfizer, Merck, EUSA Pharma, and CMR Surgical; travel expenses from Pfizer; and speaker fees from Pfizer. G.D.S. is Clinical lead (urology) National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. The remaining authors declare no financial or non-financial competing interests.
